{
  "docId": "019de074-71be-772a-8bed-f9d5eaece76b",
  "docSlug": "e4f10758c80bf7a23f09bd201ccd4281",
  "documentTitle": "Alkermes | Investor Presentation Deck | 32 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 32,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 7,
  "notes": "Includes a callout regarding COVID-19 impact on 2020 sales.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-71be-772a-8bed-f9d5eaece76b/14",
  "deckHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b",
  "deckJsonHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b.json",
  "deckAnchorHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.08,
        "x": 0.725,
        "y": 0.395
      },
      "kind": "callout",
      "text": "COVID-19 Impact",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5445902-4d24-4615-9ba0-72252aed0e77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.63,
        "w": 0.42,
        "x": 0.485,
        "y": 0.215
      },
      "kind": "chart",
      "text": "VIVITROL Net Sales ($M)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b431153-4f54-40ee-9a64-27293f22c38c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.875
      },
      "kind": "disclaimer",
      "text": "Full prescribing information for VIVITROL may be found at www.vivitrol.com/content/pdfs/prescribing-information.pdf. Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca1e4fcc-dc3d-4310-8b97-63f5a6bbc087",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.17,
        "y": 0.7
      },
      "kind": "image",
      "text": "VIVITROL product packaging",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c341e6e1-1fba-4d4b-923d-292c9ae6a288",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Extended-release opioid antagonist provides therapeutic levels of naltrexone for a one-month period. Indicated for the treatment of alcohol dependence (AD). Indicated for the prevention of relapse to opioid dependence (OD).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87ccb963-b432-4b50-8403-6b6a109a2a4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "VIVITROL®: LAI for the Treatment of Opioid Dependence and Alcohol Dependence",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b54ac19-4219-4b07-8a94-31741009e52d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 8,
      "beatId": "94c87527-871a-454f-af4f-75bda8022c1a",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "LYBALVI prescription growth trends, ALKS 2680 clinical development plan",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}